

SOT | Society of Toxicology

Creating a Safer and Healthier World
by Advancing the Science of Toxicology

2011–2012 COUNCIL

December 31, 2011

PRESIDENT

Jon C. Cook,
Ph.D., ATS, DABT
Pfizer Global Research
and Development

VICE PRESIDENT

William Slikker Jr.,
Ph.D., ATS
U.S. FDA-NCTR

VICE PRESIDENT-ELECT

Lois D. Lehman-
McKeeman,
Ph.D., ATS
Bristol-Myers Squibb
Company

TREASURER

John B. Morris,
Ph.D.
University of Connecticut

SECRETARY

Peter L. Goering,
Ph.D., ATS, DABT
U.S. FDA-CDRH

SECRETARY-ELECT

Judith T. Zelikoff,
Ph.D.
New York University
School of Medicine

PAST PRESIDENT

Michael P. Holsapple,
Ph.D., ATS
Battelle

COUNCILORS

Donald A. Fox,
Ph.D., ATS, FARVO
University of Houston

Dori R. Germolec,
Ph.D.

Research Triangle Park, NC

John C. Lipscomb,
Ph.D., ATS, DABT
U.S. EPA/ORD/NCEA

Michael P. Waalkes,
Ph.D.
Research Triangle Park, NC

EXECUTIVE DIRECTOR

Shawn Douglas Lamb

Dear Voting Member of the Society of Toxicology:

The Nominating Committee, including Chairperson Cheryl Lyn Walker, Laura Andrews, Deborah A. Cory-Slechta, Vicki L. Dellarco, Marion F. Ehrich, Michael F. Hughes, Jane Ellen Simmons, Robert S. Skoglund, Kimberley Anne Treinen, and Council Contact Michael P. Holsapple is proud to present the 2012–2013 nominees for SOT officers and members of SOT elected committees.

Please mark the ballot in the appropriate spaces and be sure to include your signature and printed full name. Blank spaces are provided for write-in candidates. Fax the ballot, with the accompanying cover sheet that also includes your signature, printed full name, and address, to the offices of Dixon Hughes Goodman, LLP (Certified Public Accountants); Fax: 240.403.3701, Attn: E. Smith.

Your ballot will be valid only if you have printed and signed your name on both the fax cover sheet and the ballot sheet. **All valid ballots received by February 1, 2012, will be counted.**

Alternatively, you may chose to vote using the online ballot processes, available on the SOT website at www.toxicology.org/ms/2012Ballot.aspx. Just log in using your email and SOT password to gain access to the ballot. After you review the candidate biographical information, make your selections by marking the appropriate spaces next to the candidates' names, or complete text fields for write-in candidates.

Thank you for participating in this important election process. Follow the results in the Special Issue of the *Communiqué* in late February. I hope that your 2011 was most successful and satisfying and that I have the pleasure of seeing you in March at our Annual Meeting in San Francisco, California.

Sincerely,



Peter L. Goering
Secretary

Enclosures

1821 MICHAEL FARADAY DRIVE, SUITE 300, RESTON, VIRGINIA 20190
Telephone: 703.438.3115 Fax: 703.438.3113 Email: sothq@toxicology.org
Website: www.toxicology.org

Society of Toxicology

1821 MICHAEL FARADAY DRIVE, SUITE 300, RESTON, VIRGINIA 20190
Telephone: 703.438.3115 Fax: 703.438.3113 Email: sothq@toxicology.org
www.toxicology.org

Ballot facsimile transmittal

To:	E. Smith, SOT Ballot Clerk	Company:	Dixon Hughes Goodman, LLP
Phone:		Fax:	240.403.3701
From:		Date:	
Phone:		Very Important:	Ballot Reply

Please Fax this page and the
Ballot Card to **240.403.3701**.
Ballot cards faxed to SOT will not be counted.

**Only Ballots faxed
by February 1, 2012,
will be counted.**

The following must be completed:

Signature

Printed Name

Address

Please Deliver Immediately

Society of Toxicology

1821 MICHAEL FARADAY DRIVE, SUITE 300, RESTON, VIRGINIA 20190
Telephone: 703.438.3115 Fax: 703.438.3113 Email: sothq@toxicology.org
www.toxicology.org

Ballot Card

SOCIETY OF TOXICOLOGY OFFICIAL BALLOT 2012-2013

(Nominees are listed by office, in reverse alphabetical order.)

The following is required:

Member's Signature

Printed Name

**Only Ballots faxed
by February 1, 2012,
will be counted.**

Ballots must be
returned with the Ballot
transmittal cover page
and faxed to Dixon
Hughes Goodman, LLP
240.403.3701.

VICE PRESIDENT-ELECT (vote for only one)

- Norbert E. Kaminski
- Ronald N. Hines
- _____

TREASURER-ELECT (vote for only one)

- Denise Robinson Gravatt
- Myrtle A. Davis
- _____

COUNCILORS (vote for no more than two)

- Ivan Rusyn
- Lori A. Dostal
- Joy A. Cavagnaro
- Lorrene A. Buckley
- _____

AWARDS COMMITTEE (vote for no more than three)

- Nancy Monteiro-Riviere
- B. Paige Lawrence
- Mary E. Gilbert
- Yvonne P. Dragan
- Samuel M. Cohen
- Michael Aschner
- _____

MEMBERSHIP COMMITTEE (vote for no more than two)

- Tao Wang
- Mari S. Stavanja
- J. Christopher States
- Michelle J. Hooth
- _____

NOMINATING COMMITTEE— FROM THE MEMBERSHIP-AT- LARGE

- (vote for only one)
- Martin A. Philbert
 - Nancy D. Claude
 - Richard A. Becker
 - _____

NOMINATING COMMITTEE— FROM REGIONAL CHAPTERS (vote for only one)


- Andrew M. Seacat
- Gloria B. Post
- Stephen M. DiZio
- Rosonald R. Bell
- _____

NOMINATING COMMITTEE— FROM SPECIALTY SECTIONS (vote for no more than two)

- Jeffrey J. Yourick
- John A. Wisler
- Thomas R. Sutter
- Alison C. P. Elder
- Jeanine L. Bussiere
- James V. Bruckner
- Norman J. Barlow
- _____

Please Deliver Immediately





BIOGRAPHICAL SKETCHES FOR 2012–2013 ELECTION

Nominees are listed in reverse alphabetical order.

Vice President–Elect (*Vote for one of two*)

Norbert E. Kaminski, PhD



Employer: Michigan State University

Year Joined SOT: 1983

Schools Attended: North Carolina State University, PhD, Toxicology & Physiology, 1985; North Carolina State University, MS, Toxicology, 1981; Loyola University of Chicago, BA, Chemistry, 1978.

SOT–Elected Positions: Treasurer–Elect 2004–2005, Treasurer 2005–2007.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Council Subcommittee for Regional Chapter Funding 2003–2005; Endowment Fund Board 2006–present, Chair 2011–present; Endowment Implementation Task Force Co-Liaison 2005–2007; Finance Committee 1999–2007, Council Contact, Chair 2005–2007; NIH Funding Task Force Council Contact 2005–2007; World Wide Web Advisory Committee Council Contact 2004–2005; Immunotoxicology Specialty Section 1986–present; Michigan Regional Chapter 2002–present, Counselor 1996–1997.

Experience: Dr. Kaminski is a professor of pharmacology and toxicology and director of the Center for Integrative Toxicology at Michigan State University. He holds joint appointment in the College of Human Medicine and Veterinary Medicine at Michigan State University. Dr. Kaminski joined the Michigan State faculty in 1993. Dr. Kaminski held the rank of assistant professor at the Medical College of Virginia in the Department of Pharmacology and Toxicology (1985–1999). Dr. Kaminski has served on advisory panels including National Academy of Science/IOM Review of the Health Effects in Vietnam Veterans of Exposure to Herbicides (1992–1994); US EPA Science Advisor Board–Dioxin Reassessment Review (1995); National Academy of Sciences IOM Study on the Assessment of the Health Implications of Exposure to Dioxins (2004–2006); and Michigan Environmental Science Board (2004–2007). Dr. Kaminski has also served on peer review panels including US EPA Science Review Panel for Health Research (1990–1992); NIH ALTX-4 Study Section as a member (1998–2003); and as an *ad hoc* member for NIDA, NIEHS, NIOSH, Wellcome Trust, and chair of an American Chemistry Council Peer Review Panel (2001). Dr. Kaminski was an associate editor for the *Journal of Pharmacology and Experimental Therapeutics* (2004–2009), served on the *Toxicological Sciences* Editorial Board (1998–2008), is a Founding member of the Editorial Board for *Nonlinearity in Biology, Toxicology and Medicine*, and is currently on the Editorial Board for the journals *Toxicology* and *Journal of Immunotoxicology*. Dr. Kaminski served as a member of Council as well as chair of the Membership Committee for the Society on NeuroImmune Pharmacology. Dr. Kaminski is on the Board of Trustees for ILSI (International Life Sciences Institute) Health and Environmental Sciences Institute (HESI) (2003–present) and currently serves as treasurer.

Goals for SOT: The SOT is a continuously evolving and dynamic global scientific society with membership from all sectors of toxicology, including industry, academia, and government. My goal for the SOT is to enhance the perception of toxicology as a scientific discipline to those in other areas of science and to the general public. A multifaceted approach of engagement, communication, and education would be used to achieve this goal, which at its core would be focused on the quality of science being conducted by those in our discipline. In addition, I fully embrace the current SOT strategic vision of “building for the future,” which must include a long-term strategy for recruiting and training the brightest students to serve as our next generation of toxicologists.

Ronald N. Hines, MS, PhD, ATS



Employer: Medical College of Wisconsin

Year Joined SOT: 1991

Schools Attended: University of Texas Southwestern Medical School, PhD, Biochemistry, 1980; Roswell Park Memorial Hospital Division, State University of New York at Buffalo, MS, Natural Sciences, 1976; University of Oklahoma, BS, Zoology, 1975.

SOT–Elected Positions: Councilor 2008–2010.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Contemporary Concepts in Toxicology Conferences Committee Council Contact 2009–2010; Continuing Education Committee 1995–1998, Chair 1998, Council Contact 2008–2010; Council Subcommittee for Non-SOT Meeting Funding Council Contact, Chair 2009–2010; Council Subcommittee for Non-SOT Meeting, Component & Global Funding Co-Chair 2009–2010; Council Subcommittee for Regional Chapter Funding 2008–2010, Council Contact 2009–2010, Chair 2009–2010; Data Task Force 2009–present; FDA/NCTR Government Liaison Group Ex-Officio Member 2010–2011; Membership Committee Council Contact 2008–2009; NIH Funding Task Force 2004–2008, Chair 2007–2008, Council Contact 2008–2010; Postdoctoral Assembly Executive Board Council Contact 2008–2009; Postdoctoral Representatives Council Contact 2008–2009; Science Strategy Committee 2005–2007; Scientific Liaison Task Force Council Contact 2009–2010; Task Force to Improve the Scientific Basis of Risk Assessment 1999–2002, Chair, 2002; Carcinogenesis Specialty Section 1996–1999; Mechanisms Specialty Section 2008–present; Reproductive and Developmental Toxicology Specialty Section 1998–2007; Molecular Biology Specialty Section 1996–present, Vice President-Elect 1993–1994, Vice President 1994–1995, Councilor 1992–1993, President 1995–1996, Past President, Councilor 1996–1997; Reproductive and Developmental Toxicology Specialty Section Councilor 2002–2003; Michigan Regional Chapter, President-Elect 1996–1997, President 1997–1998, Councilor 1998–1999.

Experience: Dr. Hines' academic experience includes being a postdoctoral fellow at the University of Vermont College of Medicine in biochemistry from 1980–1983 and work as an assistant professor at the Eppley Institute for Research in Cancer and Allied Diseases & Department of Biochemistry at the University of Nebraska Medical Center from 1983–1988. Dr. Hines then continued as an associate professor at the Eppley Institute for Research in Cancer and Allied Diseases & Department of Biochemistry at the University of Nebraska Medical Center from 1988–1989. In 1989, he worked as associate professor of pharmacology at Wayne State University School of Medicine until 1995. From 1994–1999, Dr. Hines was an associate of pediatrics in the division of clinical pharmacology and toxicology at Wayne State University School of Medicine. In 1995, Dr. Hines worked as a professor of pharmacology for four years (until 1999) at the Wayne State University School of Medicine. In 1999, Dr. Hines continued his career as professor of pediatrics and pharmacology / toxicology at the Medical College of Wisconsin, where he is currently employed.

Dr. Hines' administrative experience includes serving as assistant program leader for the Chemical Carcinogenesis Program at Myer L. Prentis Comprehensive Cancer Center of Metropolitan Detroit from 1990–1995. Dr. Hines serviced the Clinical Pharmacology Training Faculty at Wayne State University and Children's Hospital of Michigan for seven years (1992–1999). In 1994, Dr. Hines worked as a director for the Regulation of Gene Expression Research Core at NIEHS Environmental Health Sciences Center for Molecular and Cellular Toxicology with Human Applications at Wayne State University from 1994–1997. From 1997 through 1999, Dr. Hines continued his work at NIEHS Environmental Health Sciences Center for Molecular and Cellular Toxicology with Human Applications at Wayne State University as the deputy director. Currently Dr. Hines is co-director in the Birth Defects Research Center at Children's Hospital of Wisconsin (since 1999). He also is co-section chief of clinical pharmacology, pharmacogenetics and teratology within the Department of Pediatrics at the Medical College of Wisconsin (since 2003). In addition, Dr. Hines is currently an associate director at the Children's Research Institute at the Children's Hospital and Health Systems (since 2005) and the deputy director at NIEHS Children's Environmental Health Sciences Core Center, a joint initiative between the University of Wisconsin Milwaukee, the Children's Research Institute, and Medical College of Wisconsin (since 2009).

Dr. Hines has served on numerous Editorial Boards such as *Toxicology Letters*, 1993–1995; *Drug Metabolism & Disposition*, 1994–present; *Chemical Research in Toxicology*, 1995–1997; *Archives of Biochemistry & Biophysics*, 1995–2006; *Journal of Pharmacology & Experimental Therapeutics*, 1997–2000; *Chemico-Biological Interactions*, 1998–2009; and also as an associate editor of *Toxicology & Applied Pharmacology*, 1996–2004; *Birth Defects Research (A)*, *Clinical & Molecular Teratology*, 2003–2006; *Journal of Pharmacology & Experimental Therapeutics*, 2000–present; and *Chemico-Biological Interactions*, 2009–present.

Dr. Hines' selected service experience includes: being a member of the NIH DRG Toxicology I Study Section from 1994–1995; a member and chair for the NIH DRG Alcohol and Toxicology I Study Section from 1996–1999; a chair for the Mechanisms of Toxicity Gordon Research Conference in 2002; a member of the NIEHS/NTP CERHR Expert Panel on Ethylene Glycol and Propylene Glycol from 2002–2003; a member and chair of the NIEHS/NTP CERHR Expert Panel

on Fluoxetine; a member of ILSI Health & Environmental Sciences Institute Board of Trustees from 2002–present; vice chair 2010–present; and member of the EPA FQPA Scientific Review Board from 2003–present; a member of the FDA /NCTR Scientific Advisory Board from 2009–present; a member of the NIEHS EHS Review Committee from 2010, and as chair from 2011–2014.

Dr. Hines has also received the following honors and awards: NRSA predoctoral fellowship, 1977–1980; Danish Cancer Society Travel and Visiting Professorship Award, 1987; Wayne State University Board of Governors Distinguished Faculty Fellow Award, 1998–2000; Society of Toxicology AstraZeneca Traveling Lectureship, 2001; March of Dimes Leadership Award in Research, 2005; elected fellow of the Academy of Toxicological Sciences, 2007.

Goals for SOT: Although challenged by our economic climate, we are in an era of unprecedented opportunity for the toxicology discipline. We are just beginning to harvest some of the benefits of the human genome project, but equally important, advances in epigenetics are providing clues as to how the environment communicates with the genome to alter its functionality in both adaptive and adverse ways. Innovation in the field has also led to major advances in exposure biology, allowing us to accurately and rapidly assess low-level exposures and internal dose metrics. Advances in proteomics and metabolomics have provided a wealth of information on how such environmental exposures perturb cellular and systemic signaling systems. These advances and the wealth of data being generated have substantially increased the need for novel bioinformatics and also have provided the substrate for increasingly accurate and useful computational approaches for predictive toxicology. Finally, recognition of these advances has led to a re-evaluation of how we will conduct toxicology testing in the future and how that information will be used in human risk assessment. We already are seeing the development of highly innovative platforms for high-throughput testing. My goals and objectives for the Society of Toxicology will be to ensure our organization leads in promoting and facilitating continued advances in our science for the benefit of our members and to ensure that we grow in our role as a resource to our membership, government, and society. We are fortunate our recently updated strategic plan provides an outstanding road map for accomplishing these objectives and for achieving success in our mission of creating a safer and healthier world by advancing the science of toxicology.

Denise Robinson Gravatt, PhD



Employer: Pfizer, Inc.

Year Joined SOT: 1992

Schools Attended:

Georgetown University,
PhD, Pharmacology,
1986; George Washington
University, MS,
Pharmacology, 1982;
University of Cincinnati, BS,
Biology, 1978.

SOT-Elected Positions: Councilor 2007–2009; Membership Committee 2002–2005.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Animals in Research Committee Council Contact 2007–2009; Committee on Diversity Initiatives Council Contact 2007–2009; Communications Committee Council Contact 2008–2009; Communications Task Force 2004–2005; Council Subcommittee for Non-SOT and Contemporary Concepts in Toxicology 2008–2009; Council Subcommittee for Non-SOT Meeting Funding 2008–2009; Council Subcommittee for Regional Chapter Funding 2007–2009; Global Strategy Task Force 2009–2012; Regulatory Affairs and Legislative Assistance Committee 1999–2002, Chair 2000–2001; Carcinogenesis Specialty Section 1997–2008; Comparative and Veterinary Specialty Section 1997–2005; Drug Discovery Toxicology Specialty Section 2005–present; Food Safety Specialty Section 1996; Mechanisms Specialty Section 1997–2011; Occupational and Public Health Specialty Section 1997; Regulatory and Safety Evaluation Specialty Section 1999–present, Councilor 2000–2002, Secretary / Treasurer 2002–2003; Reproductive and Developmental Toxicology Specialty Section 1996–1997; Risk Assessment Specialty Section 1999–present; Toxicologic and Exploratory Pathology Specialty Section 2005; Women in Toxicology Special Interest Group 2007–present; National Capital Area Chapter 1994–2002, Vice President 2002; Northeast Regional Chapter 2002–present.

Experience: Dr. Robinson Gravatt is currently a senior director and head of science and technology in Drug Safety R&D at Pfizer in Groton, Connecticut. She is responsible for broad science-based research strategies across the global Pfizer organization to address long-standing safety issues related to drug development. These research strategies encompass internal laboratory research and external technology development and investment strategies, including postdoctoral fellowships, external collaborations, and other partnerships. Prior to joining Pfizer in 2002, Dr. Robinson Gravatt was the founding director of the ILSI Health and Environmental Sciences Institute, a nonprofit organization devoted to advancing the application of toxicological sciences to risk assessment and risk management. Dr. Robinson Gravatt has been active in a number of external scientific organizations, including SOT, American College of Toxicology, Society for Risk Analysis, ToxForum, the Critical Path Institute (CPI), and the Innovative Medicines Initiative (IMI). She serves on the Advisory Committee of the CPI's Predictive Safety Testing Consortium, the Steering Committee and Scientific Advisory Committee for IMI's SAFE-T Consortium, and contributes to the Program Committee for Toxicology Forum.

Goals for SOT: The Society's fundamental strengths include the expertise, talent, and energy of its membership, as well as the leadership's vision to evolve the organization for the benefit of our membership and constituencies. The implementation of SOT's Strategic Plan over the past eight years has positively influenced the Society's growth and relevancy but must be regularly refreshed to reflect SOT's experience and growth in size, diversity, and global reach. How we direct SOT's resources to most effectively wield the considerable influence that SOT can bring to bear upon current public health and environmental issues requires active debate and decision-making.

To meet the future needs of its members, the scientific and regulatory communities, and society as a whole, SOT must maintain its strong financial foundation. I hope to use my organizational and financial experience to positively impact SOT's continued development. My aspirations and goals include the following:

- Stewardship of SOT's assets in an uncertain economic climate, including the endowment fund and future opportunities to build revenue for SOT's long range strategic priorities.
- Create and increase opportunities for impact, including advocacy for funding for basic, mechanistic and applied research, contributing to science based policy making, and supporting tools and training programs for the future of the discipline.
- Reinforce SOT's efforts to attract scientists from diverse fields and backgrounds. The multidisciplinary nature of our discipline is one of our strengths and also key to increased impact.
- Advocate for outreach to other scientific societies with similar interests and goals. Such partnerships will help to increase the impact and visibility of our science.
- Support the continued maturation of the SIGs, expanding the roles of the Specialty Sections, and strengthening of the Regional Chapters. The most creative ideas are often generated in the smaller settings such as these groups provide for toxicologists to work together.

Myrtle A. Davis, DVM, PhD



Employer: NIH-NCI

Year Joined SOT: 1992

Schools Attended:

University of Illinois
Champaign-Urbana, PhD,
Toxicology & Veterinary
Biosciences. 1992;
Tuskegee University
School of Veterinary
Medicine, DVM, 1988;
Tuskegee University,
Undergraduate work in
Chemistry, 1984.

SOT-Elected Positions: Membership Committee 2000–2003; Nominating Committee 2004–2006.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Committee on Diversity Initiatives *Ad Hoc* Member 2003–2006; Communications Committee 2011–present; Minority Subcommittee 1996–2002; Regulatory Affairs and Legislative Assistance Committee 2005–2006; Scientific Program Committee 2008–present; Biological Modeling Specialty Section 2004; Carcinogenesis Specialty Section 1996–2006; Cardiovascular Toxicology Specialty Section 2011–present; Comparative and Veterinary Specialty Section 1996–present, Vice President-Elect 2003–2004, Vice President 2004–2005, President 2005–2006, Past President 2006–2007; Drug Discovery Specialty Section 2006–present; Immunotoxicology Specialty Section 2000–2003; Risk Assessment Specialty Section 1996–1997; Toxicologic and Exploratory Pathology Specialty Section 2000–2003; Central States Regional Chapter 2002–2006; National Capital Area Regional Chapter 2011–present.

Experience: Dr. Davis is currently the Branch Chief for toxicology and pharmacology in the Division of Cancer Treatment and Diagnosis of the National Cancer Institute. Her current responsibilities include providing toxicology expertise to project and program teams in drug discovery through first human dose, creating and leading major research initiatives within DTP, and managing the daily operations of the toxicology and pharmacology branch. Dr. Davis came to NIH from Lilly Research Labs, Eli Lilly and Company, where she held the position of Research Advisor in the Investigative Toxicology Group. Prior to taking the position at Eli Lilly, Dr. Davis was an associate professor in the Department of Pathology at the University of Maryland, School of Medicine where she had an active research program exploring mechanisms of toxicant-induced apoptosis and the role of protein phosphorylation. Dr. Davis began her professional career with a postdoctoral fellowship in toxicologic pathology at the University of Maryland in 1994.

Goals for SOT: My primary goal is to serve as a key contributor to the Finance Committee and encourage the discussion of creative ideas and recommendations that link educational initiatives with sustainable financial support. I will also be a strong supporter of the Society's goal to create a public awareness of the past, current, and future contributions of the science of toxicology to public health.

Ivan Rusyn, MD, PhD



Employer: University of North Carolina Chapel Hill

Year Joined SOT: 1998

Schools Attended: University of North Carolina at Chapel Hill, PhD, Toxicology, 2000; Ukrainian State Medical University (Kiev, Ukraine), MD (with Honors), 1994.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Board of Publications 2008–present, Chair 2011–present; Program Committee 2005–2008; Carcinogenesis Specialty Section 1998–present, Councilor 2007–2009, Secretary / Treasurer 2010–present; Mechanisms Specialty Section 1999–present; North Carolina Regional Chapter 2001–present.

Experience: Dr. Rusyn is currently a professor at the University of North Carolina at Chapel Hill. Prior to becoming a professor in 2010 he was the associate professor (with tenure from 2007–2010) and was the assistant professor in the Department of Environmental Sciences & Engineering (from 2002–2007). Since 2002, Dr. Rusyn has been a member and associate director (2005–2011) of the Curriculum in Toxicology Program at the University of North Carolina at Chapel Hill. Since 2008, he is the director at the Carolina Center for Computational Toxicology—Gillings School of Global Public Health at UNC at Chapel Hill. For the past six years, Dr. Rusyn has also been the scientific co-director at Carolina Environmental Bioinformatics Center—Gillings School of Global Public Health, UNC at Chapel Hill. Since 2003, he has been an active member of various centers including being a full member of the Lineberger Comprehensive Cancer Center, School of Medicine, UNC at Chapel Hill; a member of the Bowles Center for Alcohol Studies, School of Medicine, UNC at Chapel Hill; a member of the Center for Environmental Health and Susceptibility; and a member of the Carolina Center for Genome Sciences (since 2002). Other relevant experience includes IARC monographs 101 and 96; National Research Council (NRC) standing Committee on Use of Emerging Science for Environmental Health Decisions; the NRC committees on tetrachloroethylene and formaldehyde; the EPA Science Advisory Board Committee on trichloroethylene; XNDA study section (permanent member); he is a member of the North Carolina Department of Environment and Natural Resources, Science Advisory Board; and is also serving on the editorial boards of *ToxSci* and *TAAP*.

Goals for SOT: The Strategic Plan outlines the priorities for the Society for 2012–2015. As a Chair of the Board of Publications, I had a chance to provide input and agree with all goals and objectives stated. As a member of Council, I will focus my attention on the following goals first as I believe I have relevant expertise and knowledge to make impact:

- **Build for the future of toxicology:** As a former administrator in one of the premier toxicology training programs I have the intimate knowledge of the challenges and opportunities in educating future toxicologists. I believe that a survey of the training programs and degrees may be needed and an attempt made to share best practices in recruiting students into careers in toxicology and environmental health sciences, course and curriculum design, research, and hands-on training opportunities for students to prepare them for diverse career opportunities.
- **Promote the recognition of toxicology:** Next several years are likely to be crucial for legislative reform on environmental regulation. The Society is in the position to provide scientific expertise to the lawmakers and other interested parties and the membership needs to be mobilized to ensure that TSCA reform is based on best available science and is protective of public health.

**Lori A. Dostal, PhD,
DABT**



Employer: Exponent, Inc.

Year Joined SOT: 1988

Schools Attended:

University of North Carolina, PhD,
Pharmacology, 1983;
University of Michigan,
BS, Microbiology, 1978.

SOT-Elected Positions: Awards Committee 2009–2011; Nominating Committee 2006–2008.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Program Committee 2002–2006; Comparative and Veterinary Specialty Section 1996–1997; Regulatory and Safety Evaluation Specialty Section 1996–present; Reproductive and Developmental Toxicology Specialty Section 1998–present, Councilor 1996–1997, Vice President-Elect 2006–2007, Vice President 2007–2008, President 2008–2009, Past President 2009–2010; Women in Toxicology Special Interest Group 2001–2003; Michigan Regional Chapter 2002–present; Midwest Regional Chapter 2005–2008.

Experience: For the past year, Dr. Dostal has been employed at Exponent, Inc. where she is a nonclinical pharmaceutical development consultant. She works in all areas of toxicology including IND enabling, nonclinical strategy, safety issue resolution, reproductive and developmental toxicology, and juvenile animal toxicology to support pediatric drug development. From 2007–2010, Dr. Dostal worked at Aptuit Consulting Inc. as a pharmaceutical development consultant in all areas of toxicology: general, reproductive and developmental toxicology, juvenile animal toxicology studies, and nonclinical strategy. Prior to Dr. Dostal's work at Aptuit Consulting Inc., she worked for a total of nineteen years at Warner-Lambert/Parke-Davis and Pfizer, Inc. For five years (2003–2007) she was senior director and research associate at the Drug Safety Research & Development Department and was the Therapeutic Area Leader for antibacterial drug development and participated on multisite drug development teams. From 2001–2003, she was the director of reproductive and developmental toxicology at Pfizer, Inc. in Ann Arbor, Michigan. Also, while working at Warner-Lambert, she served as director/senior research associate in endocrine toxicology (1999–2001) and as senior scientist in reproductive and developmental toxicology, general and genetic toxicology, and was a drug development team toxicology representative (1988–2007). Dr. Dostal is a diplomate of the American Board of Toxicology.

Goals for SOT: As a member of SOT Council I would work to provide opportunities for broader membership interactions, improving Annual Meeting involvement, and increasing the accessibility of committees and awards to students and early career toxicologists. Diversity of opinions and open-minded evaluation of the facts in the Society of Toxicology is an important component of an influential society such as SOT. I believe that a balance of conservative and proactive views and encouragement of an entrepreneurial spirit best serves the diverse membership as a whole.

**Joy A. Cavagnaro, PhD,
DABT, RAC, Fellow ATS,
RAPS Fellow**



Employer: Access BIO LC

Year Joined SOT: 1986

Schools Attended:
University of North
Carolina at Chapel Hill,
PhD, Biochemistry, 1979;
University of Miami, BS,
Biology, 1975.

SOT-Elected Positions: Education Committee 2001–2004.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: 40th Anniversary Task Force 2000–2001; Committee on Diversity Initiatives 2001–2004; Committee on Public Communications 1997–2000, Chair 1999–2000; Communications Task Force 2004–2005; Education Subcommittee for Minority Initiatives Chair 2001–2002; Regulatory Affairs and Legislative Assistance Committee 1994–1997, Chair 1996–1997; Toxicology Specialist 1998–1999; Biotechnology Specialty Section 2009–present, Councilor 2011–present; Comparative and Veterinary Specialty Section 1996–1997; Women in Toxicology Special Interest Group 2010; National Capital Regional Chapter 1992–present, Councilor 1993–1995, Treasurer 1995–1997, President 1999–2000, Past President 2000–2001.

Experience: Dr. Cavagnaro is president and founder of Access BIO, consultancy specializing in science-based regulatory strategies and development services to facilitate biomedical research, emerging technologies, and product development. Her career spans academia, the CRO and biotechnology industries, and government. Dr. Cavagnaro's academic career began as a National Toxicology Fellow at Duke University School of Medicine, followed by research assistant and associate professorships at Boston University School of Medicine. She served as principal study director for biotechnology products at Covance (formerly Hazleton Labs) and vice president of Regulatory Affairs and Integrated Compliance Human Genome Sciences. During her tenure at CBER/FDA she was appointed to the SBRS and served as FDA's safety topic lead and rapporteur for "ICH S6." She was past chair of RAPS and founder, past chair and member of the Leadership Committee of BioSafe, an expert preclinical science committee within BIO. Dr. Cavagnaro served as US BIO representative to the 2006 ABPI/BIA Early Stage Clinical Trials Taskforce. She was the past North American chair of DIA's Biotech Special Interest Area Committee (SIAC) and is currently a member of Research and Development SIAC Liaison to the ACNA Executive Committee. Dr. Cavagnaro was past chair of the Clinical and Regulatory Affairs Committee and is currently a member of the Translational Science & Product Development Committee of the ASGCT. Currently Dr. Cavagnaro is a chair of CRRI, an independent IRB, regulatory reviewer for California Institute of Regenerative Medicine Grants and a member of SACATM. She was editor of *Preclinical Safety Evaluation of Biopharmaceuticals A Science-Based Approach to Facilitating Clinical Trials* published by John Wiley & Sons, New Jersey, 2008 and contributed a chapter to *Comprehensive Toxicology ed.* by C. A. McQueen (2010). This year, Dr. Cavagnaro was recipient of the 2011 Career Achievement Award presented by the SOT Biotechnology Specialty Section.

Goals for SOT: The combination of my SOT and professional career experiences has provided me a unique perspective regarding the pivotal position that SOT plays as a leader in advancing the science of toxicology. SOT provides an important platform where solutions to complex challenges relating to human, animal, and environmental health can evolve from many different neutral perspectives. I will use my broad experience as the basis for contributing to discussions and decisions to shape SOT's mission and goals as it continually evolves as a dynamic leading toxicology organization. I believe that it is essential to engage SOT members in determining the toxicology of tomorrow. I feel Council needs to work closely with membership and SOT staff to keep abreast of emerging issues. I will help efforts to globally deliver the best opportunities for innovations in learning, networking, and professional development in toxicology. As a member of Council, I would apply my talents to support SOT's worldwide contributions to a safer and healthier 21st century. I have had the opportunity to serve on several SOT committees in the past as well as participate in annual meetings as presenter, chair, and lecturer in continuing education courses. In addition, the positions I have held as chair and leader of different organizations have taught me to not only develop new concepts and ideas but also the importance of joint ventures/star alliances. SOT has a great value proposition to take advantage of collaborations to better realize its mission. It would be a pleasure to serve in a leadership capacity to support the implementation of SOT's vision and expand its global imprint. I will continue to advocate and support the new generation of rising toxicology stars [I promise this time to get that calendar out!]. Championing science-based, rational, innovative, and relevant toxicology... "To love what you do and feel that it matters—how could anything be more fun?"

Lorrene A. Buckley, PhD



Employer: Eli Lilly & Company

Year Joined SOT: 1985

Schools Attended:
University of North Carolina at Chapel Hill, PhD, Toxicology 1992; University of Arizona, Tucson, Arizona, MS, Toxicology, 1980; State University College of New York at Geneseo, BS, Chemistry, 1978.

SOT-Elected Positions: Education Committee 2009–present, Chair 2011–present.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Committee on Public Communications 2002–2004; Education Subcommittee: ToxLearn Work Group Education Committee Liaison 2010–present; Placement Committee 1996–1999 Co-Director 1997, Director 1998; Comparative and Veterinary Specialty Section 1996–1997; Drug Discovery Specialty Section 2008–2010; Neurotoxicology Specialty Section 2003; Regulatory and Safety Evaluation Specialty Section 2000–present, Councilor 2010–present; Risk Assessment Specialty Section 2005; Women in Toxicology Special Interest Group 1995–present; Mid-Atlantic Regional Chapter 1984–1988; North Carolina Regional Chapter 1980–1984 and 1988–1992, Newsletter Editor 1983–1984; Ohio Valley Regional Chapter 1996–present.

Experience: Dr. Buckley has a diversity of professional experience in toxicology that is reflected in her work spanning basic research, agro-chemical toxicology and risk assessment, and pharmaceutical safety assessment. Her years of experience and leadership roles on various SOT Committees (Career Resource and Development and Education) as well as with “sister” organizations (e.g., ABT Board, ACT Council) are especially relevant to her qualifications for candidacy for Councilor on the SOT Council.

Goals for SOT: For SOT to have real and positive impact on improving global health, the Society must effectively implement tactics that directly support the Strategic Plan. Especially important to meeting SOT’s central challenge to enhance the impact and recognition of toxicology will be our ability to “build for the future”—to attract young scientists to the field and to develop these new (as well as mature) scientists technically and professionally by providing opportunities for quality education and training. Also key to success is the facilitation by SOT of effective partnerships within constituent groups (e.g., academia, government/regulatory, industry) as well as with other professional organizations. Finally, SOT must continue to strive for clear and impactful communication with external audiences and to stand for the integrity of the science in all sectors of toxicology practice.

Nancy Monteiro-Riviere, PhD, ATS



Employer: North Carolina State University

Year Joined SOT: 1986

Schools Attended: Purdue University, PhD, Anatomy / Cell Biology 1981; Purdue University, MS, Anatomy / Cell Biology 1979; Stonehill College, BS, Biology, 1976.

SOT-Elected Positions: Nominating Committee 2001–2002.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Board of Publications 2003–2007, Chair 2006–2007; Comparative and Veterinary Specialty Section 1996–2007; Dermal Toxicology Specialty Section 2000–present, Vice President-Elect 2002–2003, Vice President 2003–2004, President 2004–2005, Past President 2005–2006; *In Vitro* and Alternative Methods Specialty Section 1996–present, Secretary / Treasurer 1998–1999, Vice President-Elect 1999–2000, Vice President 2000–2001, President 2001–2002, Past President 2002–2003; Nanotoxicology Specialty Section 2007–present; Women in Toxicology Special Interest Group 2009–present; North Carolina Regional Chapter 1982–present.

Experience: Dr. Monteiro-Riviere is a professor at North Carolina State University, (1995–present) and professor of the Joint Department Biomedical Engineering at University of North Carolina at Chapel Hill and North Carolina State. She is an adjunct professor at the University of North Carolina at Chapel Hill's Dermatology Department in the School of Medicine. She is currently a member in the American College of Toxicology. In addition she is fellow in the Academy of Toxicological Sciences and the American Society of Nanomedicine. Dr. Monteiro-Riviere served on several Editorial Boards including: *Fundamental and Applied Toxicology* 1992–1998; *Microscopy Research and Technique*, Guest Ed. *Dermatotoxicology* 1995–1996; *Toxicological Sciences* 1998–2000; *Toxicology Methods* 1997–2001; *Toxicology Mechanisms & Methods* 2002–2010; and is currently on the *Journal of Applied Toxicology* 2000–present; *Cutaneous and Ocular Toxicology* 2001–present; *Toxicology In Vitro* 2003–present; *Nanotoxicology* 2009–present; *Nanomedicine* 2010–present; associate editor *WIREs in Nanomedicine and Nanobiotechnology* 2005–2008 planning, 2008–present; and an associate editor *Materials Science & Engineering C: Materials for Biological Applications* 2007–present. Dr. Monteiro-Riviere was grant reviewer for DoD and NIH. She serves on many national and international panels including: US EPA—FIFRA, ILSI and HESI, NIEHS Scientific Advisory Committee on Alternative Toxicological Methods (SACATM) 2002–2007, International Council on Nanotechnology (ICON), The National Academies Research Council Committee to Review the Federal Strategy for Engineered Nanoscale Materials, and National Nanotechnology Initiative (NNI). She has received extramural research grants from DoD, NIOSH, NIH, and industrial sources. Her research interest has focused on assessing both *in vitro* and *in vivo* model systems for skin absorption and toxicity of environmental and novel pharmaceutical chemicals, and nanomaterials. Dr. Monteiro-Riviere has also organized several SOT CE courses and workshops in skin toxicology and nanotoxicology. Her books include: Co-Ed. *Nanotoxicology: Characterization, Dosing and Health Effects* and editor of *Skin Toxicology*. Additionally, Dr. Monteiro-Riviere was recipient of the Purdue Distinguished Women Scholars Award. Dr. Monteiro-Riviere began her professional career with a CIIT-The Hammer Institutes for Health Sciences, postdoctoral fellow in toxicology, 1982–1984.

Goals for SOT: To promote and enhance public awareness of toxicology and to educate and train students for the next generation of toxicologists. The Society should continue to be active both in National and International organizations that need the advice of toxicologists for government regulatory decisions. SOT should actively ensure that its membership and activities remain balanced across academic, industrial, and government interest.

B. Paige Lawrence, PhD



Employer: University of Rochester Medical Center

Year Joined SOT: 2000

Schools Attended: Cornell University, PhD, Biochemistry and Cell Biology, 1993; Skidmore College, BA, Biology / Chemistry, 1986.

SOT-Elected Positions: Education Committee 2004–2007.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: K–12 Subcommittee 2004–2007, Education Liaison 2005–2006, Co-Chair 2004–2007; Immunotoxicology Specialty Section 1997–present, Councilor 2002–2004; Reproductive and Developmental Toxicology Specialty Section 2005–present; Women in Toxicology Special Interest Group 2002–present; Pacific Northwest Regional Chapter 2003–2007, Councilor 1999–2002.

Experience: Dr. Lawrence is associate professor of environmental medicine and microbiology and immunology at the University of Rochester Medical Center. Her research focuses on understanding how environmental signals affect the function of the mature and developing immune system, with particular focus on fighting infections. She is an associate editor of *Toxicological Sciences*, and serves on editorial boards for several other journals. She has been active in various SOT activities, including the Education Committee and the Immunotoxicology Specialty Section.

Goals for SOT: I would like to help SOT advocate for the needs of toxicologists, through a strong commitment to fostering education in toxicology, the recruitment of students and new scientists into the field, and by providing the world's foremost forum for presenting the best science that relates to toxicology and environmental health.

Mary E. Gilbert, PhD



Employer: US EPA

Year Joined SOT: 1999

Schools Attended: University of Western Ontario, PhD, London, Ontario, Canada 1983; University of Western Ontario, MS, London, Ontario, Canada 1981; Trent University, BSc, Peterborough, Ontario, Canada 1980.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Neurotoxicology Specialty Section 1998–present, Secretary / Treasurer 2002–2006; North Carolina Regional Chapter 2003–present.

Experience: Dr. Gilbert is a neurotoxicologist in the National Health and Environmental Effects Laboratory at the US Environmental Protection Agency. Her research has examined alterations in brain function, plasticity, and behavior following exposure to pesticides, metals, and hormone-disrupting chemicals. The impact of low-level thyroid hormone disruption in brain development in rodent models has been the primary focus of her work over the last five years. She has mentored several students and postdoctoral fellows and holds an adjunct position in the Department of Psychology at the University of North Carolina at Chapel Hill. Dr. Gilbert sits on the editorial board for two specialty journals in her field, *Neurotoxicology* and *Neurotoxicology and Teratology* and is an active reviewer for toxicology, neuroscience, and neuroendocrinology journals. A member of SOT for 12 years, Dr. Gilbert has been active in the Neurotoxicology Specialty Section (NTSS) where she served as secretary / treasurer for four years. As an NTSS member and as secretary / treasurer, she worked with the NTSS council to encourage the active participation of students and postdocs in the NTSS poster competition at the SOT Annual Meeting. As an officer of NTSS, Dr. Gilbert was active in the selection of two of NTSS Distinguished Investigator awardees, an award given to recognize an individual who has made substantial and seminal scientific contributions to the discipline of neurotoxicology over a protracted period. Dr. Gilbert is also a member of the Society for Neuroscience and active in the Neurobehavioral Teratology Society (NBTS) where she has served as councilor, chair of finance, chair of nominations, a member of the Public Affairs Committee, and in 2006, as NBTS president. Dr. Gilbert began her professional career with postdoctoral training at McMaster University, Hamilton, Ontario, Canada 1986.

Goals for SOT: I believe it is important for the Society to recognize outstanding individuals for their scientific contributions, their training of toxicologists, their education of the public sector as well as demonstrated leadership and societal and community service. I will work hard to increase awareness of the existence of these awards to the membership and actively encourage members to apply. Many awards from SOT support graduate and undergraduate student travel to the meeting. I believe this should be based on both merit and need as many smaller institutions may not be in a position to provide compensation to worthy students. I feel strongly that this venue serve as a valuable mechanism to both attract quality individuals to the discipline in the early stages of their career, and to keep them as members of the Society. I will be committed to maintaining a high standard and the even application of reliable metrics for determining award winners across all award types.

Yvonne P. Dragan, PhD



Employer: AstraZeneca Pharmaceuticals LP

Year Joined SOT: 1986

Schools Attended: Medical College of VA, PhD, Pharmacology and Toxicology, 1988; Smith College, BA, Biology, 1981.

SOT-Elected Positions: Councilor 2004–2006.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Continuing Education Committee 1998–2001, Chair 2001, Council Contact 2005–2006; Council Subcommittee for Regional Chapter Funding 2005–2006; Education Committee Council Contact 2004–2006; SOT Liaison Representative, AAAS 2011–present; Carcinogenesis Specialty Section 1996–present, Secretary/Treasurer 1994–1998, Vice President-Elect 1998–1999; Vice President 1999–2000, President 2000–2001, Past President 2001–2002; Drug Discovery Toxicology Specialty Section 2005–present; Mechanisms Specialty Section 1996–present; Molecular Biology Specialty Section 1996–2005; Regulatory and Safety Evaluation Specialty Section 2005–present; Mid-Atlantic Regional Chapter 2007–2011; Northeast Regional Chapter 2011–present; Ohio Valley Regional Chapter, Vice President-Elect 1999–2000, Vice President 2000–2001, President 2001–2002; Past President 2002–2003; South Central Regional Chapter 2003–2006.

Experience: Dr. Dragan is currently the associate director of Global Safety Assessment in the US and head of molecular and investigative toxicology at AstraZeneca Pharmaceuticals since 2007. From 2002–2006, Dr. Dragan served at the National Center for Toxicological Research, FDA, where she was the head of the Hepatotoxicity Program from 2002–2006, and the director of the Division of Systems Toxicology from 2005–2007. She was also a member of the Interagency Pharmacogenomics Review Group and the Voluntary Genomics Submission Analysis Team. From 1998–2001, she worked as an assistant professor at the Ohio State University, School of Public Health, where she was also a member of the Environmental Molecular Science Institute. In addition, Dr. Dragan worked for ten years in the McArdle Laboratory at the University of Wisconsin-Madison (1988–1998). While she was at the University of Wisconsin-Madison she served as a research associate professor (1997–1998), a research assistant professor (1991–1997), and a postdoctoral fellow in chemical carcinogenesis (1988–1991).

Goals for SOT: The Society of Toxicology celebrates its diverse successes and impact on human health and environmental well being in part through its award process. The awards system allows us to recognize the great work and the exceptional individuals and teams that comprise our Society. In addition, the awards permit us to continuously raise the bar in defining what it means to be a toxicologist and an active member of our society. It is the contributions that we make every day from our science to our mentoring to our publications or public speaking that define us as scientific contributors to the debates on human and environmental health and policy decisions. It is our communication strategies from hallway conversations to regulatory debates that define the future directions of toxicology and science in general, as well as science based policy decisions. Our future as a discipline and as a society depends on our strong pipeline of proactive individuals (students, teachers, mentors, consultants, policy makers, regulators) who seek to better human health and the environment through measured science, discourse, and debate. The awards process allows us to celebrate the successes along the path of our shared vision of increased scientific impact and expanded engagement in the society for today's members and future leaders. If elected to serve on the Awards Committee, I will be a proactive advocate for toxicology, its diverse interests and the individuals who contribute to increasing our scientific and regulatory impact to define the future of toxicology.

Samuel M. Cohen, MD, PhD, ATS, DABP



Employer: University of Nebraska Medical Center

Year Joined SOT: 1986

Schools Attended: University of Wisconsin, MD, PhD, Experimental Oncology, 1972; St. Vincent Hospital, Worcester, MA, Pathology Residency, 1975; Board Certified in Anatomic and Clinical Pathology, 1976.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Task Force to Improve the Scientific Basis of Risk Assessment 1999–2002; Biological Modeling Specialty Section 2000; Carcinogenesis Specialty Section 1997–present, Vice President-Elect 2000–2001, Vice President 2001–2002, President 2002–2003, Past President 2003–2004; Comparative and Veterinary Specialty Section 1996–1997; Immunotoxicology Specialty Section 2000; Mechanisms Specialty Section 2000; Risk Assessment Specialty Section 1998–present; Toxicologic and Exploratory Pathology Specialty Section 1999–2000; Central States Regional Chapter 2002–present, President 2004–2005, Past President 2005–2006.

Experience: Dr. Cohen has dedicated thirty years (1981–present) as a professor of pathology and microbiology and the Eppley Cancer Center at the University of Nebraska Medical Center where he currently resides. While at the University of Nebraska Medical Center, Dr. Cohen was chairman of the Department of Pathology and Microbiology from 1992–2007 and previously vice chairman from 1981–1992. Dr. Cohen’s career also includes working at St. Vincent Hospital in Worcester, Massachusetts as a staff pathologist from 1975–1981. He worked overseas as a visiting professor in the first Department of Pathology at the Nagoya City University, Nagoya, Japan from 1976–1977. Among Dr. Cohen’s extensive career he has served as a member on a number of panels including: NIH, EPA, FDA, NAS, IARC, and IPCS. He has been a member of the Board of Trustees at the International Life Sciences Institute (ILSI) and ILSI Health and Environmental Sciences Institute (HESI). Dr. Cohen is a member of the Scientific Board of Counselors, National Toxicology Program from 2002–2004 and NIEHS from 2008–present. Dr. Cohen does consulting for several companies. He has greater than 300 publications in peer review journals. Dr. Cohen has also been a recipient of the prestigious SOT Arnold J. Lehman Award in 2001.

Goals for SOT:

- Emphasize science in toxicology and risk assessment.
- Increase awareness of toxicology principles in medical professionals, the media, and the general public.

Michael Aschner, PhD, ATS



Employer: Vanderbilt University Medical Center

Year Joined SOT: 1986

Schools Attended: University of Rochester, School of Medicine, PhD, Neurobiology / Anatomy 1985; University of Rochester, School of Medicine, MS, Anatomy 1983; Toxicology University of Rochester, BS, Natural Sciences 1980.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Placement Committee 1992–1995, Chair 1994–1995; Research Funding Committee 2010–present; Scientific Program Committee 2007–2010; Comparative and Veterinary Specialty Section 1996–1997; Metals Specialty Section 2000–2006; Neurotoxicology Specialty Section 1996–present, Vice President-Elect 1995–1997, Secretary / Treasurer 1992–1994, President 1997–1998, Councilor 1998–1999; North Carolina Regional Chapter 2005–2004; Southeastern Regional Chapter 2010–present.

Experience: Dr. Aschner has served on numerous national and international toxicology panels (Institute of Medicine, US Environmental Protection Agency, Center for Disease Control), served and chaired a National Institutes of Health study section, and he has authored approximately 400 peer-reviewed manuscripts and chapters in the area of neurotoxicology. He serves as associate editor (*Neurotoxicology; Toxicological Science*) and on the editorial boards (*Toxicology; Acta Neurobiologiae Experimentalis; Alcohol; Neurochemical Research*) of several journals and he edited several books related to neurotoxicology. He is a member of the Society of Toxicology, Society for Neuroscience, a fellow of the Academy of Toxicological Sciences, and a past president of the International Neurotoxicology Association. In 2011, Dr. Aschner was a recipient of the SOT Merit Award.

Dr. Aschner's research interests are in the neurobiology and physiology of astrocytes and the mechanisms of central nervous system injury. Dr. Aschner has been particularly interested in metal uptake and distribution in the brain, devoting the last 25 years of his research to the mechanisms of transport of methylmercury, manganese, and uranium across the capillaries composing the blood–brain barrier, as well as their cellular and molecular mechanisms of neurotoxicity. Studies in the lab address basic mechanisms in various experimental models (*C. elegans*, tissue cultures and rodents) as well as follow-up on the sequelae of manganese deposition in the brains of human neonates.

He also has mentored numerous graduate and postdoctoral students and has recently assumed the responsibility for the T32 NIH training grant in molecular toxicology. Dr. Aschner began his professional career with a postdoctoral fellowship at the University of Rochester, School of Medicine in 1987.

Goals for SOT:

- To foster closer collaborations both within the US and globally.
- Enhance training funds for students.
- Increase the visibility of toxicology as a science.
- Increase the awareness of toxicology in the population and large, explaining our role in addressing disease processes, interactions between environment and genes, and the principles that influence regulatory risk assessment.

**Tao Wang, MD, PhD,
DABT**



Employer: Novartis

Year Joined SOT: 1997

Schools Attended:

University of Louisiana at Monroe, PhD, Pharmacology/Toxicology, 2000; Bethune University of Medical Sciences, MD, 1993.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Continuing Education Committee 2010–2013; Global Strategy Task Force 2010–present; Regional Chapter Communication and Collaboration Committee 2010–present, Chair 2011–present; Special Interest Group Collaboration Committee 2010–present; American Association of Chinese in Toxicology Special Interest Group Councilor 2010–2012; Women in Toxicology Special Interest Group 2007–present, Councilor 2010–present; Carcinogenesis Specialty Section 2010–2011; Cardiovascular Specialty Section 2010–2011; Mechanisms Specialty Section 2000; Regulatory and Safety Specialty Section 2009–2011; Northern California Regional Chapter 2006–present, Secretary 2007–2008, Vice President-Elect 2008–2009, Vice President 2009–2010, President 2010–2011, Past President 2011–present; Pacific Northwest Regional Chapter 2002–2005; South Central Regional Chapter 1997–2000.

Experience: Dr. Wang received her MD degree from the Norman Bethune University of Medical Sciences in 1993, and her PhD in pharmacology and toxicology from the University of Louisiana in 2000, which was followed by a postdoctoral position at the University of Washington from 2000–2002. Dr. Wang is currently a senior investigator (associate director) in the Preclinical Safety Department at Novartis Pharmaceuticals. Dr. Wang leads safety assessment for oncology and anti-infectious drug development projects, evaluates results from preclinical studies, and provides overall opinion regarding risk assessment in support of clinical trials. Dr. Wang represents the Preclinical Safety Department as a toxicology expert on global project teams, and presents key preclinical safety data on drug candidates to Novartis Global Management teams. She leads multiple target teams within the Preclinical Safety Department by designing and implementing investigative and mechanistic studies addressing preclinical safety issues. Dr. Wang is also responsible for evaluating high-cost in-licensing opportunities for Novartis by reviewing preclinical safety data from the target-company, drug exposure data, clinical efficacy and safety data, and identifying potential safety risks. Based on these analyses Dr. Wang formulates a recommendation as to whether or not the in-licensing consideration should proceed. Dr. Wang received the Novartis Above & Beyond Award in 2006 and a Due Diligence Award in 2010. In 2011, Dr. Wang received the Novartis Catalyst Award in recognition of her outstanding contributions to Novartis, an award given to those who have demonstrated extraordinary achievement and performance beyond work requirements. In addition, Dr. Wang participates in the teaching of the *Practical Toxicology* course at the University of California at Berkeley as a guest lecturer. She also serves as a reviewer for the *International Journal of Toxicology*. Dr. Wang has been actively involved in the Society of Toxicology (SOT), approaching all leadership roles with tremendous energy and success. Dr. Wang is a diplomate for the Board of American Board of Toxicology.

Goals for SOT: The SOT Strategic Plan for 2012–2015 identified the goals of attracting, training, and retaining toxicologists, fostering integration of basic sciences that support the evolution of toxicology, and promoting the integrative role of toxicology to other scientific disciplines as the top priorities for the Membership Committee over the next three years. As a member of the Membership Committee, I will devote my energy to the development of new approaches and incentives to support SOT’s Strategic Plan and increase SOT activities in the following areas:

- Increase international membership and expand global interactions to enhance the global impact of toxicology on public health, and to foster improved scientific and global regulatory harmonization;
- Increase membership among scientists from all related disciplines, with the goal of expanding the breath of existing programs as a mechanism to maintain the interest of current members, and to reaffirm and promote the role and advantages of toxicology in the integration of diverse scientific disciplines; and
- Identify novel approaches and incentives to enhancing and maintaining membership among pre- and postdoctoral trainees, with the goal of enhancing and sustaining a membership base for the future.

If elected, I will approach these tasks with the same energy and dedication that I have brought to all of my previous leadership roles and work tirelessly to promote the global mission of SOT.

Mari S. Stavanja, BS, MSc, PhD



Employer: Celanese International Corporation

Year Joined SOT: 1995

Schools Attended: New Mexico State University, PhD, Animal Science, 1994; New Mexico State University, MS, 1990; Instituto Tecnológico y de Estudios Superiores de Monterrey, Campus Queretaro, Mexico (ITESM-Qro). BS, 1982.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Committee on Diversity Initiatives 2006–2009, Chair 2008–2009; Professional Needs Assessment Task Force 2010–present; Special Interest Groups Task Force 2005–2007; Hispanic Organization of Toxicologists Interim Executive Committee 2004–2008; Carcinogenesis Specialty Section 2003; Comparative and Veterinary Specialty Section 1996–1997; Inhalation Specialty Section 2001–present; Regulatory and Safety Specialty Section 1995–present; Reproductive and Developmental Toxicology Specialty Section 1996; Risk Assessment Specialty Section 2006–present; Hispanic Organization Special Interest Group 2006–2011, President 2008–2009, Past President 2009–2010; Women in Toxicology Special Interest Group 1995–present; Gulf Coast Regional Chapter 2009–2011; North Carolina Regional Chapter 2007–2009.

Experience: Dr. Stavanja's experience includes eighteen years of professional experience in the field of toxicology and regulatory affairs. She specializes in hazard evaluation of chemicals including single chemical, pesticides, and food additives and their impact on human and environmental health. Dr. Stavanja also has extensive experience in interpreting the State and Federal laws in the US and worldwide regulations, by country, pertaining to requirements set for registration of chemical substances. In addition she is highly knowledgeable in compiling documentation required for certification and registration of chemicals, pesticides, tobacco products, and food additives in the US and in foreign countries. Dr. Stavanja's experience also includes the ability to design, monitor, perform experiments, evaluate biological endpoints, and compile safety/toxicological reports/assessments. Dr. Stavanja is fully versed in reviewing and evaluating internal and external toxicology reports to identify hazards, develop mitigation plans and meet worldwide regulatory compliance requirements.

Goals for SOT: As a member of SOT for more than 16 years, I consider this Society the ideal place to exchange ideas with colleagues from multiple backgrounds and affiliations. As such, I am committed to work hard to improve the already growing membership by attracting colleagues. I also plan to look into non traditional areas to illustrate the importance of toxicology to other potential members. Improving the way to connect among members utilizing ToXchange is another of my priorities since understanding each other and communicating to the public is one of the most important aspects of our role as toxicologists.

J. Christopher States, PhD



Employer: University of Louisville

Year Joined SOT: 1997

Schools Attended: Albany Medical College, Union University, PhD, Pathology and Molecular Biology, 1980; State University of New York at Buffalo, BS, Biochemistry, 1974.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Cardiovascular Toxicology Specialty Section 2010–present; Metals Specialty Section 1997–present, Secretary/Treasurer 2005–2007, Vice President-Elect 2009, Vice President 2010, President 2011–present; Molecular Biology Specialty Section 1997–present; Reproductive and Developmental Toxicology Specialty Section 2008–present; Ohio Valley Regional Chapter 2002–present, Councilor 2006–2010, Vice President 2011–present.

Experience: Dr. States is currently a professor, distinguished university scholar, and director of graduate admissions and recruitment in the Department of Pharmacology and Toxicology. He is also deputy director at the Center for Genetics and Molecular Medicine and deputy director at the Center for Environmental Genomics and Integrative Biology at the University of Louisville School of Medicine. Dr. States has had prior academic positions at Wayne State University (1988–1999), Children's Hospital Research Foundation, and University of Cincinnati (1984–1988). He currently serves on the several editorial boards including: *Toxicology and Applied Pharmacology* 2007–present; *Reproductive Toxicology* 2007–present; and the *Journal of Ovarian Research* 2008–present. He has frequently served as a grant reviewer for NIH and other federal and international agencies/foundations.

Goals for SOT: To make SOT the preeminent authority for toxicology, to make toxicology accessible to the public, and to recruit young people into the field.

**Michelle J. Hooth, PhD,
DABT**



Employer: NIEHS-NTP

Year Joined SOT: 1999

Schools Attended:
University of North
Carolina at Chapel
Hill, PhD, Toxicology,
1996; Michigan State
University, BS, Biological
Sciences, 1990.

SOT-Elected Positions: Education Committee 2004–2007, Chair 2006–2007.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Committee on Diversity Initiatives (CDI) 2004–2006, Co-Chair 2004–2005, Education Liaison to CDI 2005–2006; Continuing Education Committee 2009–2010; Carcinogenesis Specialty Section 1999–present, Councilor 2006–2008; Women in Toxicology Special Interest Group 2002–present, Vice President 2001–2002, President 2002–2003, Past President 2003–2004; North Carolina Regional Chapter 1990–present, Councilor 2003–2005.

Experience: Dr. Hooth currently serves as the group leader of the General Toxicology Group, a division of the National Toxicology Program (NTP) at NIEHS. The primary function of this group is to evaluate and characterize the toxicologic and/or carcinogenic potential of specific chemicals and/or agents nominated to the NTP for assessment. Dr. Hooth serves as a project leader for a number of chemicals at various stages of the evaluation process; she is particularly interested in metal toxicity and evaluation of commonly used herbal medicines/dietary supplements. She currently leads the NTP Safe Drinking Water Program that identifies and characterizes health risks associated with exposure to drinking water disinfection by-products, other chemical contaminants, and algal toxins. She also coordinates the preparation and publication of the NTP technical reports including toxicity, Technical and Genetically Modified Model (GMM) reports. Dr. Hooth is an active member of SOT and has been involved with SOT in many areas. She was a founding member of the Women in Toxicology Special Interest Group.

Goals for SOT: As a member of the committee, I would look for ways to encourage individuals to become active members of the Society and to encourage current members to continue to renew and progress through the various membership levels. To accomplish this, the Society needs to effectively communicate and promote the benefits of membership and ensure that the application/renewal process is not onerous. More importantly, it is my goal to ensure that membership in the Society is viewed as inclusive, diverse, and responsive to the needs of its members.

Martin A. Philbert, PhD, ATS



Employer: University of Michigan

Year Joined SOT: 1995

Schools Attended:
University of London
Royal Postgraduate
Medical School, PhD,
Neurochemistry and
Neurotoxicology, 1989.

SOT-Elected Positions: Awards Committee 2005–2007, Chair 2006–2007; Secretary-Elect 2007–2008; Secretary 2008–2010.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Awards Committee 2005–2007, Chair 2006–2007; Secretary-Elect 2007–2008; Secretary 2008–2010. 50th Year Anniversary SOT Task Force 2006–2011, Council Contact 2009–2010, Chair 2010–2011; Council Subcommittee for Non-SOT and Contemporary Concepts in Toxicology Council Contact, Chair 2008–2009; Council Subcommittee for Non-SOT Meeting Funding 2007–2010, Council Contact, Chair 2008–2009; Council Subcommittee for Non-SOT Meeting, Component, & Global Funding 2007–2010, Co-Chair 2009–2010; Council Subcommittee for Regional Chapter Funding 2007–2010, Council Contact, Chair 2008–2009; Council Subcommittee on Social Networking 2009–2010; Data Task Force 2009–2011; Education Subcommittee for Minority Initiatives 1996–1999; Endowment Fund Board 2010–present; NIH Funding Task Force Council Contact 2007–2008; NIOSH Government Liaison Group Ex-Officio Member 2010–2011; Research Funding Committee Council Contact 2008–2010; Lake Ontario Regional Chapter 2002–2006; Michigan Regional Chapter 2010–2011; Midwest Regional Chapter 2009–2011.

Experience: Dr. Philbert is professor of toxicology and dean of the University of Michigan School of Public Health. He received his PhD in neurochemistry and neurotoxicology in 1989 from the University of London Royal Postgraduate Medical School. After a brief postdoctoral fellowship in neurotoxicology at Rutgers University, he assumed the position of research assistant professor. In 1995, he joined the toxicology faculty at the University of Michigan School of Public Health where he served as senior associate dean for research 2004–2010. He has served on the NIEHS study section to review training grants, program projects, center grants, etc., and as a regular member of the ALTOXIII/NAL study section. Dr. Philbert also provided advice to the director of the NIEHS on Council and currently serves as the chair of both the US EPA Board of Scientific Counsellors and the US FDA Science Advisory Board. He was vice chair of the NRC Committee that reviewed the National Nanotechnology Initiative's Environmental, Health, and Safety Strategy. He has had a continuously funded portfolio of academic research in toxicology, neurotoxicology, nanotechnology, and nanotoxicology since 1990 and has received support from NIEHS, US EPA, NCI, DoD-DARPA, USAF, and the WM Keck Foundation. He was appointed to the nanotechnology technical advisory group for the Presidents' Science Advisory Council under the 43rd president of the United States.

Goals for SOT:

- To promote the science of toxicology in making the world a safer and healthier place.
- To identify and recruit candidates with a passion for the science of toxicology and the advancement of the field.
- To identify, recruit, mentor, and promote junior scientists to service roles in the Society.
- To promote diversity of all kinds within the Society.
- To promote collegial and collaborative leadership that is representative of all sectors of the Society.
- To promote global engagement in Society leadership.

Nancy D. Claude, PhD, ERT



Employer: Servier Group

Year Joined SOT: 2000

Schools Attended:
University of Paris,
PhD, Toxicology, 1982;
University of Paris,
Doctor in Pharmacy,
1982.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Regulatory and Safety Evaluation Specialty Section 2003.

Experience: Dr. Nancy Claude, PhD, doctor in pharmacy from the Faculty of Paris, has more than 20 years of experience in the pharmaceutical industry. She is currently director of drug safety in Servier Group in Suresnes, France. With a team of 110 people, she is leading efforts in investigative and regulatory toxicology.

Dr. Claude has been an active member of the SOT since 2000. She also served the French Society of Toxicology (currently past president), EUROTOX (2010–2012 president) and organized EUROTOX 2011 in Paris in August 2011. She is a member of the French Academy of Pharmacy.

Additionally, Dr. Claude also has some teaching responsibilities and has contributed to more than 70 publications and communications.

Goals for SOT: During the ten last years, I have seen the SOT dramatically growing with a strong effort of internationalization. As a member of the Nominating Committee, my main goal would be to strengthen participation of toxicologists from all nationalities to encourage global communication and education in toxicology in the various parts of the world. In addition, I would like to encourage new and young members to support the SOT vision of a healthier world.

Richard A. Becker, PhD, DABT



Employer: American
Chemistry Council

Year Joined SOT: 1990

Schools Attended:
University of
California, Irvine,
PhD, Pharmacology
and Toxicology, 1982;
Swarthmore College, BA,
Chemistry, 1977.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Congressional Science Fellowship Review Subcommittee Chair 2002–2003; Regulatory Affairs and Legislative Assistance Committee 2000–2003, Chair 2002–2003; Regulatory and Safety Evaluation Specialty Section 2011; Risk Assessment Specialty Section 2011; National Capital Area Regional Chapter 2002–2009.

Experience: Dr. Becker joined the American Chemistry Council in 1999, where he continues to serve as the organization's senior toxicologist in addressing emerging health risk science issues, including advanced risk assessment techniques, biomonitoring, sensitive subpopulations, endocrine screening and testing, and alternative test methods. His research interests include mechanisms of toxicity, risk assessment, development of screening methods for determining endocrine activity of environmental agents, development and application of biomonitoring equivalents to interpret human biomonitoring results in a risk context, and integrated testing employing toxicity triggers to reduce animal testing of industrial chemicals. Dr. Becker has published in all of these areas. Dr. Becker has served as an elected officer in the Society for Risk Analysis (councilor), where he chaired the Membership Committee and in the International Society of Regulatory Toxicology and Pharmacology, where he served as secretary. Dr. Becker is currently a member of the SRA Finance Committee. In addition, Dr. Becker has chaired and continues to participate in SOT symposia and workshops, and has chaired or served on a number of workshop/project organizing committees. Prior to relocating to Washington, DC, Dr. Becker was with the State of California from 1987 to 1999, holding positions as a senior toxicologist in the Department of Toxic Substances Control, the deputy director of scientific affairs in the California Environmental Protection Agency's Office of Environmental Health Hazard Assessment (OEHHA), and subsequently serving as director of OEHHA by gubernatorial appointment. Dr. Becker began his professional career with a postdoctoral fellowship at the University of Toronto, experimental pathology, 1983.

Goals for SOT: As a member of the Nominating Committee, my major goal will be to identify the most qualified candidates to serve the Society—candidates with expertise and enthusiasm for the discipline of toxicology and vision for ways SOT can better serve SOT members and society as a whole. Thirty years ago, the Society transitioned over a period of several years from a largely descriptive discipline to a mechanistic discipline. This transition, catalyzed by the outstanding leaders of SOT, who promoted the development and application of the most advanced knowledge of how substances interact at the molecular and cellular level, and the dose-dependency of such interactions, ensured that the SOT was at the forefront of meeting the needs of society. Today, as high content and computational methods accelerate into the mainstream of toxicology practice, toxicology is again poised to evolve, and SOT again needs remarkable leaders to move us forward to better serve SOT members and society at large. These new methodologies and the resulting data must be harnessed and fully integrated to support science-based risk assessment and leaders of SOT must be the ones forging this path. The leadership of SOT has a critical role in expanding the relevance of toxicology and mode of action approaches in addressing the needs in today's world for determining chemical product safety. This becomes a particular challenge, as some have posited that biologically-based dose-response models and computational profiles built from advanced understanding of modes of action are too problematic to be used in human health safety determinations, and instead defaults should continue to be used, if not expanded. Thus the Nominating Committee has an extremely important role in identifying and recommending candidates for SOT positions who can lead the Society in addressing these challenges. I will do all I can as a Committee member to collectively identify diverse qualified candidates from all sectors who are passionate about the discipline of toxicology, dedicated to serving SOT, and committed to representing the broad interests of members.

Andrew M. Seacat, PhD, DABT

Southern California Regional Chapter



Employer: Allergan, Inc.

Year Joined SOT: 1991

Schools Attended: The Johns Hopkins University School of Hygiene and Public Health, PhD, Toxicology, 1996; University of California, Santa Cruz BA, Biology, 1986; Cabrillo College, AS, Chemistry, 1984.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Comparative and Veterinary Specialty Section 1997; Mechanisms Specialty Section 1998–present; Metals Specialty Section 2000; Co-Chair, Experimental Carcinogenesis Poster Session Committee, 2002 SOT Conference; Northland Regional Chapter 2005–2004; Southern California Regional Chapter 2005–present, Councilor 2008–2010, Vice President-Elect 2010–2011, Vice President 2011–present.

Experience: Dr. Seacat has over 20 years of experience with toxicological risk evaluation of diverse chemicals, drugs, medical devices, consumer products, excipients, and impurities. This includes nine years serving as a toxicologist at the 3M Company where he provided toxicology expertise on numerous projects for specialty chemicals, drugs, drug delivery systems, medical devices, vaccines, human risk assessment of perfluorinated acids, and lead a Strategic Toxicology laboratory. While at 3M, he also served as adjunct assistant professor in the University of Minnesota Graduate Faculty Program in the Department of Veterinary Diagnostic Medicine. He spent three years in nonclinical drug safety development for novel peptide hormone therapeutics for diabetes, obesity, and congestive heart failure at Amylin Pharmaceuticals. He has been working at Allergan Pharmaceuticals for the past four years providing toxicology support for drugs in all phases of clinical development and for product registrations in global markets; including drugs for the systemic treatment of neuropathic pain and topical ocular treatment of elevated intraocular pressure. Dr. Seacat began his professional career with a postdoctoral fellowship at Johns Hopkins University School of Hygiene and Public Health, 1996.

Goals for SOT: My goal for the Society of Toxicology is to help it become better recognized globally for what it is, a true leader in understanding and communicating the relevant and relative risks of toxic insults in our environment, food, beverages, drugs, and nutritional supplements. The Society of Toxicology is highly instrumental in bringing toxicological issues to the forefront combined with rigorous evaluation to make scientifically sound decisions. These efforts by individuals and groups within the Society are very honorable and deserve recognition from the Society. To that end, serving on the Society of Toxicology's Nominating Committee would be a great honor because of the crucial role it plays in fostering both achievements from within SOT and recognition of SOT's contributions to science and to people around the world.

Gloria B. Post, PhD, DABT

Mid-Atlantic Regional Chapter



Employer: New Jersey
Department of
Environmental Protection

Year Joined SOT: 1984

Schools Attended:
Thomas Jefferson
University, PhD,
Pharmacology, 1982;
Princeton University, AB,
Biochemical Sciences,
1977.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Occupational Public Health Specialty Section, 2008–present; Risk Assessment Specialty Section, 2000–present; Women in Toxicology Special Interest Group, 2001–present; Mid-Atlantic Regional Chapter, 1981–present, Secretary 2010–2012, Program Committee Member, 1988–1992, 2002–present, Education/Outreach Committee Member, 2010–present.

Experience: Dr. Post has been a research scientist at the New Jersey Department of Environmental Protection (NJDEP) since 1986. Her responsibilities include developing the human health basis for New Jersey's standards and guidance for environmental contaminants, coordinating risk assessment approaches used throughout NJDEP, and conducting research related to health effects of environmental contaminants. She has developed risk assessments for MTBE, perchlorate, PFOA, volatile organics found in drinking water, and many other environmental contaminants. In addition to numerous other publications, she is the first author of the chapter on Health and Aesthetic Effects of Drinking Water Contaminants in the American Water Works Association (AWWA) Handbook of Water Quality & Treatment. Dr. Post became a diplomate of American Board of Toxicology in 1990. She serves on the Exposure and Human Health Committee of the US EPA SAB, the US EPA SAB Trichloroethylene Review Panel, and on the New Jersey Drinking Water Quality Institute, a legislatively mandated advisory body to NJDEP. She is also member of the steering committee of FSTRAC, an organization of state and federal scientists responsible for human health assessment of water contaminants. She has lectured in pharmacology at Rutgers College of Pharmacy and on risk assessment at UMDNJ School of Public Health and UMDNJ Medical School. She is a reviewer for five journals. Prior to joining NJDEP, she did postdoctoral research in biochemical toxicology at Duke University and Thomas Jefferson University. Dr. Post has been an active member of the Mid-Atlantic Regional Chapter of SOT since its founding in 1981, while she was a graduate student, and has been an active member of SOT, attending as many national meetings as possible, for 28 years.

Goals for SOT: If chosen to serve on the Nominating Committee, my major objective will be to ensure that the leadership of SOT includes committed individuals who represent the diverse interests of SOT members. The primary goals of SOT should be to support basic toxicology research of the highest quality and to promote scientifically sound approaches for applying these research findings to the protection of public health and the environment. It is important that SOT programs and meetings be relevant to all SOT members including students, postdocs, and those further along in their careers in academia, industry, or government. SOT meetings and programs should include topics of interest to those who work in basic research as well as those responsible for using research results in decision-making. SOT should also continue its efforts to increase public understanding of the science of toxicology.

Stephen M. DiZio, PhD

Northern California Regional Chapter



Employer: California Department of Toxic Substances Control

Year Joined SOT: 1994

Schools Attended: University of Delaware, PhD, Genetics and Developmental Biology, 1978; Lafayette College, BA, Biology, 1972.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Animals in Research Committee 1998, Chair 1999–2000; Comparative and Veterinary Specialty Section 1996–1997; Reproductive and Developmental Toxicology Specialty Section 1996–1997; Risk Assessment Specialty Section 1994–present, Councilor 2003–2004; Mid-Atlantic Regional Chapter By-Laws Committee 1982; Northern California Regional Chapter 2002–present, Vice President-Elect 2007–2008, Vice President 2008–2009, President 2009–2010, Past President 2010–2011, Councilor 2005–2007.

Experience: After his postdoctoral fellowship at Temple University, Dr. DiZio worked as a study director in drug safety evaluation for Wyeth Laboratories from 1977–1985. He began work as a toxicologist for the California Department of Health Services in 1986. From 1992–1993, Dr. DiZio was a manager of health sciences for Environ Corporation. Dr. DiZio returned to the California Environmental Protection Agency in 1993, where he is presently the performance manager and chief of the Human and Environmental Risk Office (32 PhD toxicologists) in the California Department of Toxic Substances Control.

Goals for SOT: My short-term goals for the continued success of the national Society are to further encourage outreach to related scientific societies, such as the Society of Environmental Toxicology and Chemistry (SETAC), the Teratology Society, and the Society for Risk Analysis. This can be accomplished by vigorously encouraging the SOT Regional Chapters to hold joint conferences and symposia.

One critical objective in these days of scientific diversification is to continue to energize young investigators to participate in SOT regional and national activities. These young investigators have many choices in what they wish to be engaged in, and SOT has the challenge in demonstrating what we have to offer. These young people are our future.



Rosonald R. Bell, MSc, PhD, DABT

Mid-West Regional Chapter



Employer: Pfizer
Worldwide Research and
Development

Year Joined SOT: 1998

Schools Attended:
Florida A&M University,
PhD, Pharmacology/
Toxicology, 1992; Florida
A&M University, MSc,
Pharmaceutical Sciences,
1989; Florida A&M
University, BS, Biology/
Premedicine, 1981.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Committee on Diversity Initiatives 2011–present; Biotechnology Specialty Section 2010–2011; Drug Discovery Toxicology Specialty Section 1998–present; Immunotoxicology Specialty Section 1998–present; Molecular Biology Specialty Section 2006–2007; Regulatory and Safety Evaluation Specialty Section 1998–2005; Reproductive and Developmental Toxicology Specialty Section 1998–present; Northeast Regional Chapter 2010–2011, Councilor 2011–present; Risk Assessment Specialty Section 2008–2010; Toxicologists of African Origin Special Interest Group 2008–present, Councilor 2011–present; Mid-Atlantic Regional Chapter 2004–2005; Mid-West Regional Chapter 2002–present.


Experience: Dr. Bell received his BS in biology/premedicine from Florida Agriculture and Mechanical University in Tallahassee, Florida in 1981 and a MS and PhD in pharmaceutical sciences with a concentration in pharmacology/toxicology from Florida Agriculture and Mechanical University in 1989 and 1992, respectively. In 1992, Dr. Bell accepted a postdoctoral research position with The Upjohn Company (presently Pfizer Inc.) in Kalamazoo, Michigan (1992–1994) under the direction of Dr. Gerald J. Kolaja, where he was involved in nephrotoxicity method development as well as gaining a familiarity with nonclinical drug safety assessment. Following postdoctoral fellowship, Dr. Bell accepted a position as study director with Ciba Pharmaceuticals Corporation (presently Novartis Pharmaceuticals Corporation) in Summit, New Jersey (1994–1998) with responsibilities serving as study director as well as managing both general and reproductive toxicology groups. He became certified in general toxicology in 1996, as a diplomate of the American Board of Toxicology. In 1998, Dr. Bell accepted a position with GD Searle/Monsanto in Skokie, Illinois (1998–2003) with a primary role of Discovery and Development Project Team representative on projects in the arthritis and inflammation therapeutic area. In 2003, Dr. Bell accepted an associate research fellow position with Pfizer Inc. Dr. Bell currently serves as both a regulatory strategy lead and a drug safety team lead (DSTL) at Pfizer Inc., Groton, Connecticut, with the primarily responsible for Pre-FIH – LOE oversight of submissions and regulatory strategies. DSTL responsibilities include designing and implementing research projects to support nonclinical safety evaluation of therapeutic agents with special emphasis on inject-able anti-inflammatory biotherapeutics. He has been a member of the SOT since 1995. He is a member of the Immunotoxicology, Reproductive and Developmental, and Risk Assessment Specialty Sections. Currently he serves as a member on the SOT Committee on Diversity Initiatives, councilor for the NESOT Regional Chapter, and as member on the Executive Board of Toxicologist of African Origin Special Interest Group. His research interest is heavy induced pulmonary toxicity with special emphasis on uncovering the biochemical and cytological alterations.

Goals for SOT: As a Nominating Committee member, my focus would be to continue to help the SOT members, with membership being the foundation of SOT as an organization. The SOT is one of the most brilliant contributors to the development, dissemination, and advancement of scientific knowledge concerning the world as it exists. The balanced cross-section of members from academia, government, and industry provides a great forum for different interests and perspectives to the overall scientific pursuit and understanding of toxicology. I believe that SOT provides a critical platform for scientists and decision-makers to discuss and critique new methods of evidence development, creates new standards of scientific and decision-making excellence, and facilitates transparency in evidence-based decision making. By continuing its path of excellence and addressing the new challenges of tomorrow through creative programming, education, and service offerings, SOT and its membership will thrive as leaders of scientific creativity, rigor, and integrity, and contribute significantly to the health care challenges ahead.

I consider novel methodology and the investigation of ground-breaking techniques to expand science, education, communication, and discoveries that help to improve our understanding of toxicology as equally important and effective especially as SOT continues to develop as an organization. The SOT, like many professional societies, is facing a new reality in the service of its members. Shrinking budgets for memberships and for travel are part of that new reality. Alternative forms of communications (e.g., eLearning, podcasts, and webinars) will become the norm for the ways we link-up to one another. I am committed on a personal and professional level to encourage participation by groups and individuals who could benefit from being members of the Society and who could also make significant contributions to the Society.

Jeffrey J. Yourick, PhD, DABT

Dermal Toxicology Specialty Section



Employer: US FDA-
CFSAN

Year Joined SOT: 1993

Schools Attended:
University of Kansas,
PhD, Pharmacology and
Toxicology, 1988; Western
Michigan University,
MS, Biomedical Sciences,
1982; Kalamazoo College,
BA, Biology, 1979.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Dermal Toxicology Specialty Section 1993–present, Councilor 2006–2008, Vice President 2009–2010, President-Elect 2010–2011, President 2011–present; Nanotoxicology Specialty Section 2007–present; Reproductive and Developmental Toxicology Specialty Section 1996–1997; Risk Assessment Specialty Section 1998–2001.

Experience: Dr. Yourick is the chief of the Developmental Reproductive Toxicology and Immunotoxicology Branch at FDA/CFSAN. His current focus is on the toxicology and safety assessment (including dermal absorption and metabolism) of chemical contaminants and nanoparticles in foods, dietary supplements, and cosmetics. Previously, Dr. Yourick was the senior science and technology manager at the Defense Threat Reduction Agency (DTRA) for the Department of Defense in the area of chemical and biological defense. Dr. Yourick managed an extensive scientific research portfolio related to the development of chemical and radiological medical countermeasures. Prior to this position, Dr. Yourick was a research toxicologist for 15 years at the US FDA where his research interests pertained to skin absorption and metabolism of cosmetic ingredients and color additives. Dr. Yourick was a research pharmacologist at the US Army Medical Research Institute of Chemical Defense (USAMRICD) before joining the FDA in 1993. He was involved in investigating the biochemical mechanisms of sulfur mustard injury to the skin and lung. Dr. Yourick is a diplomate of the American Board of Toxicology. Dr. Yourick currently serves as the president of the Dermal Toxicology Specialty Section of the Society of Toxicology.

Goals for SOT: My goal for SOT is to advance our Society into the future to continue as the leading global entity in all forms of toxicological sciences. The Nominating Committee has a critical responsibility to SOT in helping to select the future leadership of our Society. Our SOT leadership must possess the expertise and vision to maintain the edge our Society has gained through past efforts, but our leadership must also have the vision and innovative nature to maintain and advance SOT as the global leading society for the science of toxicology. The function of the Nominating Committee is fundamental to moving the Society forward with strong and dedicated leadership to maintain SOT's reputation as the leading and trusted steward of toxicological sciences.

John A. Wisler, PhD, DABT

Drug Discovery Toxicology Specialty Section



Employer: Amgen, Inc.

Year Joined SOT: 1986

Schools Attended:
Indiana University, PhD,
Toxicology, 1988; Indiana
University School of
Medicine, BS, Medical
Technology, 1982; Indiana
University, BA, 1978.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Drug Discovery Toxicology Specialty Section 2007–present, Vice President-Elect 2010–2011, Vice President 2011–present; Regulatory and Safety Evaluation Specialty Section 1996–present; Biotechnology Specialty Section 2010–present; Carcinogenesis Specialty Section 2003–present; Toxicologic and Exploratory Pathology Specialty Section 2005–2010; Northern California Regional Chapter 2002–present, Councilor 2008–2010; Southern California Regional Chapter 2002–present, Councilor 2002–2003, Vice President 2003–2004, President 2004–2005, Past President 2005–2006; Ohio Valley Regional Chapter 1986–2001; Appointed by SOT to the IUTOX Toxicology Recognition Task Force 2010–present.

Experience: Dr. Wisler is currently scientific director in toxicology sciences at Amgen in Thousand Oaks, California. He has over 20 years experience of scientific toxicology leadership roles ranging from drug discovery to post marketing regulatory activities in both large and small molecule safety evaluation. Before coming to Amgen in 2003, he was a toxicology director with Allergan; a senior toxicologist with Procter and Gamble; an associate director with a CRO (IRDC/MPI); and was a National Research Council postdoctoral fellow with the US Army Institute of Chemical Defense. He is currently president of the American Board of Toxicology.

Goals for SOT: Our Society must be bold as we continue to explore novel ways to keep our current and future members engaged in the acquisition of toxicology knowledge. However, the uncertainty of global economics is becoming a financial issue for members wishing to attend national or even regional scientific meetings. SOT must expand its successful use of internet based media to offer affordable continuing education and webinars. We should also envision real-time coverage of our national SOT meeting (scientific sessions) and select regional meetings to a global audience.

Alison C. P. Elder, PhD

Nanotoxicology Specialty Section



Employer: University of Rochester Medical Center

Year Joined SOT: 1993

Schools Attended: University of California, Irvine, PhD, Toxicology, 1997; Chatham College, BS, Chemistry, 1992.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections or Regional Chapters, formerly or currently: Cardiovascular Toxicology Specialty Section 2010–present; Inhalation and Respiratory Specialty Section 2002–present; Nanotoxicology Specialty Section 2007–present; Women in Toxicology Special Interest Group 2002–present.

Experience: Dr. Elder is an inhalation toxicologist with research interests that include the pulmonary, cardiovascular, and central nervous system inflammatory and oxidative stress-related effects of engineered nanomaterials and ambient air particulate matter, and the physicochemical properties of the particles that are linked to response outcomes. Particle biokinetics and the impacts of age and other underlying vulnerabilities on response are also of interest. She has been in academia for fourteen years and has authored numerous research papers in the field, as well as review articles and book chapters. In addition to the Society of Toxicology, Dr. Elder also serves on the Threshold Limit Value-Chemical Substances Committee of the American Conference of Governmental Industrial Hygienists. She is an editorial board member of four journals and is deputy editor-in-chief of *Nanotoxicology*.

Goals for SOT: As a member of the Nominating Committee, I will strive to achieve a balance in expertise and representation for the Society's elected positions, which is essential to maintaining its vision and strength. This Society has creative and dedicated members whose involvement in leadership positions will ensure scientific excellence in academia, government, and industry and the central role of toxicologists in decision-making about the factors that affect human and environmental health.

Thomas R. Sutter, PhD

Molecular Biology Specialty Section



Employer: University of Memphis

Year Joined SOT: 1991

Schools Attended: University of Cincinnati College of Medicine, PhD, Environmental Health Sciences, 1988; St. Bonaventure University, BS, 1980.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Scientific Liaison Task Force 2008–2010; Molecular Biology Specialty Section 1996–present, Councilor 2004–2006, Vice President-Elect 2006–2007, Vice President 2007–2008, President 2008–2009, Past President 2009–2010; South Central Regional Chapter 2003–present.

Experience: Dr. Sutter is professor of biological sciences and chemistry, the Feinstone chair of molecular biology and director of the W. Harry Feinstone Center for Genomic Research at the University of Memphis (UM). Prior to joining UM in 1999, he was associate professor in the Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health. He completed his postdoctoral training at CIIT in 1991. Dr. Sutter has extensive research experience in mechanisms of toxicity and has published extensively in the field of cancer causation and prevention. He has mentored over 30 graduate students and postdoctoral fellows. He serves on several editorial boards related to toxicology and hormone action, and has been a member of multiple NIH grant review panels, and various advisory boards of the US EPA, the EU, and ILSI. Dr. Sutter is active in the Society of Toxicology, serving on committees, acting as president of the Molecular Biology Specialty Section, participating in continuing education courses, and by advancing student involvement and recognition in the Society through student awards.

Goals for SOT: As a member of the Nominating Committee, I will strive to contribute to the development of a slate of candidates for the election of SOT Council and Elected Committees that continue to represent the diversity, experience, and strengths of the entire SOT membership.

Jeanine L. Bussiere, PhD, DABT

Immunotoxicology Specialty Section



Employer: Amgen, Inc.

Year Joined SOT: 2000

Schools Attended:
Washington State
University, PhD,
Pharmacology/
Toxicology, 1989; Western
Washington University,
MS, Wildlife Toxicology,
1986; University of Idaho,
BS, Wildlife Biology, 1984.

SOT-Elected Positions: Membership Committee 2004–2007.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Placement Committee 2001–2003; Biotechnology Specialty Section 2009–2011; Carcinogenesis Specialty Section 1999; Comparative and Veterinary Specialty Section 1996–1997; Immunotoxicology Specialty Section 1996–present, Councilor 2003–2005, Vice President-Elect 2006–2007, Vice President 2007–2008, President 2008–2009, Past President 2009–2010; Women in Toxicology Special Interest Group 2004–present; Pacific Northwest Regional Chapter 2004–2005; Southern California Regional Chapter 2002–2011.

Experience: Dr. Bussiere is currently a scientific executive director of toxicology at Amgen, Inc., having moved after the acquisition of Immunex Corp. in 2002, where she was the director of pharmacology/toxicology for three years. She currently manages a group of regulatory scientists working on small molecules and proteins in several different therapeutic areas. She supports in-licensing, out-licensing and partnering efforts as well as interacts with manufacturing and protein sciences/process development on the molecular aspects that impact safety. During her time at Immunex, Dr. Bussiere was responsible for establishing the toxicology department and worked on many project teams that were responsible for all aspects of drug development, including several collaborations with outside companies, and supported research in the early development of lead candidates. Prior to joining Immunex, Dr. Bussiere was a scientist at Genentech Inc. for eight years. She worked on several collaborations with other companies and was responsible for all aspects of safety evaluation, including leading pharmacology subteams. In addition, she managed the laboratory group responsible for *in vivo* and *in vitro* pilot toxicology studies done in-house. Dr. Bussiere is a diplomate of the American Board of Toxicology and is a member of the ILSI/HESI Immunotoxicology Technical Committee, and the American College of Toxicology. She also has an affiliate faculty position with the University of Washington. Her postdoctoral work was done at Temple University School of Medicine in the area of immunopharmacology.

Goals for SOT: I believe it is important for the Society to continue to evolve and meet the needs of the future members. The Specialty Sections, Special Interest Groups, and Regional Chapters are a great way to keep current with those needs. The leadership of SOT needs to be committed to improving the link between the science and the public as well as be willing to adapt the ways of SOT to meet the changing environment.



James V. Bruckner, PhD

Biological Modeling Specialty Section



Employer: University of Georgia

Year Joined SOT: 1975

Schools Attended:
University of Michigan, PhD, Toxicology, 1974;
University of Texas, MS, Toxicology, 1971;
University of Texas, BS, Pharmacy, 1968.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Education Committee 1987–1990; Regulatory Affairs and Legislative Assistance Committee 2001–2002; Biological Modeling Specialty Section 1975–present, Vice President-Elect 2009–2010, Vice President 2010–2011, President 2011–present; Comparative and Veterinary Specialty Section 1996–1997; Mechanisms Specialty Section 1975–present; Risk Assessment Specialty Section 2010–present; Southeastern Regional Chapter, 2002–present.

Experience: Dr. Bruckner had held faculty positions at the University of Kansas, the University of Texas Medical School at Houston, and the University of Georgia (UGA). He is currently professor of pharmacology and toxicology at UGA. He founded and served as director of UGA's interdisciplinary toxicology graduate program for 15 years. Dr. Bruckner has served on a number of journal editorial boards. His primary research focus is on: metabolism, toxicokinetics, and physiological modeling of solvents; drug-solvent interactions at environmental exposure levels; and toxicokinetic bases for susceptibility of children to insecticides and other chemicals. He has published more than 200 journal articles, abstracts, and book chapters including one in *Casarett and Doull's Toxicology: The Basic Science of Poisons*. Dr. Bruckner has served on a variety of expert panels and committees for the US EPA, NIEHS, NASA, Air Force, ATSDR/CDC and NRC, most recently on the Committee on Toxicology of the National Academy of Sciences.

Goals for SOT: My goal, in running to become a member of the Nominating Committee, is to play an active role in selecting the best possible candidates for leadership positions of the Society of Toxicology (SOT). I have gained considerable experience during my 36 years as a faculty and SOT member in graduate education, federally-sponsored research addressing health effects of chemicals of major concern, and service on a variety of national panels and committees responsible for applying the best science to determine public policy. My experience, when used in cooperation with that of other scientists and regulators with different backgrounds, should be helpful in evaluating potential candidates' qualification (e.g., experience, accomplishments, leadership ability, communication skills, time to devote to specific activities, enthusiasm, ideas to improve SOT).

Norman J. Barlow, DVM, PhD, MBA, MLD, DACVP, DABT

Toxicologic and Exploratory Pathology Specialty Section



Employer: Sanofi

Year Joined SOT: 1999

Schools Attended:
Penn State University-Great Valley, MBA, 2009; Penn State University-Great Valley, Masters of Leadership Development, 2009; North Carolina State University/CIIT Centers for Health Research, PhD, Comparative Biomedical Sciences, 2003; Michigan State University, DVM, 1996; Kalamazoo College, Bachelor of Arts, 1992.

Memberships, Chairs, and/or Offices held in SOT Committees, Specialty Sections, Special Interest Groups, or Regional Chapters, formerly or currently: Toxicologic and Exploratory Pathology Specialty Section Councilor 2008–2010, Vice President-Elect 2010–2011, Vice President 2011–present; Regulatory and Safety Evaluation Specialty Section 2002; Reproductive and Developmental Toxicology Specialty Section 2000–2004; Toxicologic and Exploratory Pathology Specialty Section 1999–present; Mid-Atlantic Regional Chapter 2007–2010; North Carolina Regional Chapter 2001–2002.

Experience: Currently Dr. Barlow is employed at Sanofi in Bridgewater, New Jersey where he is the director of United States Preclinical Safety in the Disposition, Safety, and Animal Research Group. In 2008–2010, he was the associate director and head of pathology within the Drug Safety Evaluation Group at sanofi-aventis in Malvern, Pennsylvania. While he was at sanofi-aventis in Pennsylvania he also worked as a lead research investigator in the Drug Safety Evaluation Group from 2006–2008. Prior to working in Pennsylvania, Dr. Barlow worked in France at Aventis Pharmaceuticals/sanofi-aventis as an expatriate lead research investigator (drug safety evaluation and pathology) from 2004–2006. In 2003, he started as a senior principal scientist (drug safety and pathology) at Aventis Pharmaceuticals in Bridgewater, New Jersey. In addition to Dr. Barlow's pharmaceutical industry experience, he has served on several technical report peer review panels for the National Toxicology Program, as well as multiple pathology working group peer reviews of government and industry toxicology studies. He is currently a member of a Health and Environmental Sciences Institute Project Committee, Use of Imaging in Preclinical Safety Assessment.

Goals for SOT: The SOT has a rich pool of talented members, which translates into potential officers to provide leadership and guidance to the Society in coming years. A goal in seeking a position on the Nominating Committee is to help to continue to provide a slate of talented individuals for the membership to select from for representation on the SOT Council. Seeking a diverse pool of dedicated and talented individuals willing to be nominated will ensure a broad selection of candidates for members to consider in the Society's elections. An objective to achieving this goal is to interact with as many individuals as possible through networking at local meetings, the Society's Annual Meeting, and other toxicology venues. I will seek talented individuals that are willing to dedicate time to the Society for consideration by the Nominating Committee for the Society's elected leadership roles.